Table 1.
Clinical Characteristics of Study Patients Assessed by LFIA
| Variable | HD Patients (N = 39) | Transplant Recipients (N = 19) | P |
|---|---|---|---|
| Time of IgG+ test post PCR diagnosis, d | 17 [13-26] | 18 [14-23] | 0.43 |
| Age, y | 64 [58-76] | 55 [47-62] | 0.004a |
| Men | 24 (61.5%) | 12 (63.2%) | 0.91 |
| Ethnicity | |||
| White | 9 (23.7%) | 3 (16.7%) | 0.52 |
| BAME | 30 (76.9%) | 16 (84.2%) | |
| Cause of ESKD | |||
| APKD | 1 (2.6%) | 2 (10.5%) | 0.02a |
| Diabetes mellitusb | 19 (48.7%) | 3 (15.8%) | |
| Glomerulonephritis | 5 (12.8%) | 3 (15.8%) | |
| Unknown | 8 (20.5%) | 8 (42.1%) | |
| Other | 6 (15.4%) | 3 (15.8%) | |
| Baseline immunosuppression | |||
| Nob | 35 (89.7%) | 0 (0%) | <0.001a |
| Prednisolone | 1 (2.6%) | — | |
| FK only | 1 (2.6%) | 3 (16.7%) | |
| Predisolone, FK | 1 (2.6%) | — | |
| Prednisolone, FK, MMF | 1 (2.6%) | 6 (33.3%) | |
| FK, MMF | — | 7 (38.9%) | |
| Sirolimus, prednisolone, MMF | — | 2 (11.1%) | |
| Historic cytotoxic, B- or T-cell monoclonal antibody use | |||
| Nob | 34 (89.7%) | 0 (0%) | <0.001a |
| CyP | 1 (2.6%) | — | |
| CyP/Ritux | 1 (2.6%) | — | |
| Alemtuzumab | 2 (5.1%) | 16 (84.2%) | |
| IL-2R blocker | — | 1 (5.3%) | |
| CyP/bortezomib | 1 (2.6%) | — | |
| Alemtuzumab/Ritux | — | 1 (5.3%) | |
| Unknown | — | 1 (5.3%) | |
| Disease severity | |||
| Mildb | 6 (15.4%) | 12 (63.2%) | <0.001a |
| Moderate | 19 (48.7%) | 6 (31.6%) | |
| Severe | 11 (28.2%) | 1 (5.3%) | |
| Critical | 3 (7.7%) | — | |
| Care level | |||
| Outpatientb | 5 (12.8%) | 15 (78.9%) | <0.001a |
| Inpatient ward | 31 (79.5%) | 3 (15.8%) | |
| Intensive care unit | 3 (7.7%) | 1 (5.3%) | |
| Current patient status | |||
| Alive | 36 (92.3%) | 19 (100%) | 0.22 |
| Died | 3 (7.7%) | — |
Note: Values expressed as median [interquartile range] or number (percent).
Abbreviations: APKD, adult polycystic kidney disease; BAME, Black, Asian, and minority ethnic; CyP, cyclophosphamide; FK, tacrolimus; HD, hemodialysis; IgG, immunoglobulin G; IL-2R, interleukin 2 receptor; LFIA, lateral flow immunoassay; MMF, mycophenolate mofetil; PCR, polymerase chain reaction; Ritux, rituximab.
a
Statistically significant.
b
Comparator.